The Porcine Reproductive and Respiratory Syndrome Vaccine,Live (Strain R98) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a live attenuated viral active pharmaceutical ingredient intended for further manufacture into finished veterinary immunological products. The product model is the live attenuated strain R98 seed, and the API grade is supplied for downstream veterinary dosage form manufacture. The listing spans multiple presentation routes; however, the published chemistry, manufacturing, and control documentation for live PRRS virus strain R98 concentrates on parenteral lyophilized powders and frozen liquid intermediates. Published data for oral solid dosage forms containing live strain R98 is limited. The API is not a ready-to-administer vaccine and requires downstream formulation, filling, and release testing. The material is produced under a seed lot system in which the R98 seed virus is propagated in a qualified cell substrate, clarified, formulated with stabilizers, and lyophilized or filled as a frozen intermediate. Strain identity is confirmed by reverse-transcription polymerase chain reaction targeting open reading frames 5 and 7 and by nucleotide sequencing of the seed lot. Infectivity is quantified as median tissue culture infectious dose per millilitre or per gram in MARC-145 cells or porcine alveolar macrophages using the Spearman-Kärber or Reed-Muench calculation. These methods support batch release, stability monitoring, and downstream process validation.

What Distinguishes a Live Viral API from a Finished Immunological Product in Manufacture?

In a live viral API, the primary control objective is preservation of infectivity through downstream unit operations. Unlike inactivated PRRSV antigen, the R98 material cannot be exposed to high-temperature terminal sterilization, solvent-detergent treatment, or prolonged high-shear mixing without log-scale reductions in TCID₅₀. The process stream therefore uses aseptic handling of non-viral components, low-shear mixing, and controlled lyophilization. A finished injection product is usually prepared by reconstituting the lyophilized API in a sterile diluent; the API itself may be stored as a frozen liquid at −70°C or as a lyophilized cake at 2–8°C. Tablet, capsule, granule, powder, and premix presentations would require additional protective excipient strategies because the live enveloped virus is susceptible to gastric pH, bile salts, and desiccation stress. Published data for these oral presentations of strain R98 is limited, and their manufacture should be supported by virus survival studies in the intended matrix before a commercial claim is accepted. The API is differentiated from a finished vaccine by the absence of final diluent, final labeling, and final-container stability data unless those studies are conducted by the downstream marketing authorization holder.

Critical Quality Attribute Panel for the Live R98 Intermediate

Release of the live R98 API is controlled by identity, purity, potency, and safety tests. The virus titer is measured by titration in MARC-145 cells or porcine alveolar macrophages, with results expressed in TCID₅₀/g or TCID₅₀/mL. Identity is confirmed by RT-qPCR and sequencing of ORF5 and ORF7. Sterility is assessed by membrane filtration according to Ph. Eur. 2.6.1 or 9 CFR 113.26. Mycoplasma absence is evaluated by culture and indicator cell methods according to Ph. Eur. 2.6.7 or 9 CFR 113.28. Bacterial endotoxins, where applicable, are measured by limulus amebocyte lysate assay according to Ph. Eur. 2.6.14. Residual moisture in lyophilized cake is determined by Karl Fischer titration according to Ph. Eur. 2.5.12. The pH of the reconstituted material is measured by potentiometry according to Ph. Eur. 2.2.3. Appearance is evaluated by visual inspection of the cake or frozen liquid. Extraneous virus testing is performed on the master seed, working seed, and cell substrate according to the approved seed lot testing program; porcine parvovirus, bovine viral diarrhea virus, and other adventitious agents are excluded by specific assays. The release certificate should list the actual titer, moisture, pH, and sterility result for each batch, not only pass-fail entries.

Lyophilization of strain R98 intermediates follows the physical principles established for enveloped arterivirus live vaccines. The liquid API is formulated with cryoprotectants and lyoprotectants such as sucrose, trehalose, gelatin, or hydrolyzed collagen, then cooled to −45°C or below during freezing. Primary drying is conducted at subzero shelf temperatures under vacuum to remove ice by sublimation, and secondary drying is performed at elevated shelf temperatures to remove residual moisture. The collapse temperature of the formulation is measured by freeze-drying microscopy or differential scanning calorimetry, and the shelf temperature during primary drying must remain below that collapse temperature. For live PRRSV, the drying process has a narrow processing window: excessive secondary drying reduces moisture but may also reduce infectivity due to desiccation stress on the lipid envelope. Batch-to-batch variation in cake moisture, viral titer, and reconstitution time is observed on manufacturing lines when the formulation contains insufficient lyoprotectant or when the filling line hold time before freezing exceeds the qualified limit. Lyophilizers with defined load configuration and controlled nucleation steps provide more reproducible heat and mass transfer than uncontrolled shelf freezing. The container closure system is selected to provide low water vapor transmission and low oxygen transmission; elastomeric stoppers are cleaned and sterilized before use, and oxygen scavengers may be used if headspace oxygen is identified as a titer-loss driver.

When Lyophilization Excipients and Residual Moisture Determine Titer Stability

The stability of the live R98 API in dry form is governed by the glass transition temperature of the amorphous excipient matrix, residual moisture content, and oxygen headspace of the container closure. A lyophilized cake with residual moisture above approximately 3.0% may show accelerated titer loss under storage at 2–8°C because water acts as a plasticizer and lowers the glass transition temperature. A moisture level below 1.0% may cause excessive dehydration of the viral envelope and loss of infectivity. The preferred range is product-specific and must be established by forced degradation studies. The thermal degradation kinetics of strain R98 in the dried state have not been published in sufficient detail to specify an activation energy or a universal shelf-life prediction; therefore, storage temperature and shelf life are established through real-time and accelerated stability programs following VICH guidelines. The freeze-dried cake should be inspected for collapse, shrinkage, or melt-back because these defects alter the specific surface area and may change the reconstitution time. A well-formed cake reconstitutes within seconds to a few minutes, but the acceptable reconstitution time is formulation-dependent and must be stated in the downstream product specification.

Compared with inactivated PRRS virus antigen, the live R98 API contains replication-competent attenuated virus and therefore requires biosafety containment during handling. Inactivated vaccines rely on adjuvanted antigen mass and do not introduce live virus into the recipient herd; they generally require multiple administrations and generate a narrower cell-mediated immune response. Live attenuated vaccines such as strain R98 are intended to induce both humoral and cell-mediated immunity, but they carry risks of vaccine virus shedding, recombination with field virus, and reversion to virulence. The R98 seed lot is characterized to differentiate it from other modified live PRRSV strains by its passage history, ORF5 nucleotide sequence, and restriction fragment length polymorphism profile. Direct comparative field efficacy data for strain R98 against other live strains in all listed dosage forms is limited; therefore, equivalence should not be assumed without strain-specific challenge studies.

In downstream manufacture, the R98 API is aseptically transferred from the frozen or lyophilized intermediate into a controlled-environment area. For parenteral formulations, the API is thawed or reconstituted under aseptic conditions and diluted into a stabilizer-containing buffer to achieve the target potency per dose. For powder, granule, premix, or tablet forms, the live virus would require adsorption or coating onto a carrier, and the process would need to demonstrate survival through drying, compression, and storage. The mixing time, blade speed, and temperature must be controlled because high-shear granulation can generate localized heat and shear stress. Twin-screw extrusion or direct compression may be unsuitable for live enveloped virus unless the virus is protected by a lipid or polymer coating. Published data for the oral delivery of live PRRSV strain R98 is limited, and the absence of survival data in these matrices should be treated as a significant formulation risk. For injectable products, the final formulation is usually filled into glass vials under aseptic conditions and lyophilized or stored frozen. The filling line hold time is a critical process parameter because liquid live virus at ambient temperature loses infectivity over time; process validation should establish the maximum hold time. Cleaning validation for live viral API lines uses representative process residues and verifies that the cleaning agent inactivates residual virus. Dedicated equipment or campaign segregation is generally used to prevent cross-contamination with other live viral vaccine strains.

Analytical method validation for the live R98 API follows VICH GL2 principles for specificity, accuracy, precision, linearity, range, and robustness. The virus titration assay is a biological assay and therefore exhibits higher variability than chromatographic methods; a reference virus standard is included in each plate to normalize inter-assay variation. The identity assay is designed to distinguish strain R98 from other PRRSV strains by amplicon size, sequencing, or restriction enzyme digestion. During method transfer to a contract laboratory, cross-validation is required to ensure that the cell substrate passage number and serum lot do not alter the titer result. The material should be shipped in validated insulated containers with temperature loggers. For frozen liquid API, the acceptable temperature excursion during transit is defined by stability data; for lyophilized API, brief exposure to ambient temperature may be acceptable if the container closure remains intact and the exposure duration is within the qualified range. At receipt, the downstream manufacturer should verify container integrity, label information, and temperature history before quarantine release.

Scale-up from pilot to commercial scale for live PRRSV API requires attention to multiplicity of infection, cell density, and harvest time. In microcarrier bioreactor cultures or roller bottles, the cell substrate is infected at a defined multiplicity of infection, and the virus is harvested at the point where the titer reaches its maximum without excessive cell death. For PRRSV, the harvest window is commonly in the range of 48 h to 96 h post-infection; however, strain-specific harvest kinetics must be confirmed for strain R98. The clarification step uses depth filtration or low-speed centrifugation to remove cell debris without high shear. The clarified harvest may be concentrated by ultrafiltration if the titer requires adjustment, but this step can also concentrate host cell proteins and nucleic acids. The downstream purification strategy must balance titer recovery with impurity removal. Published data for strain R98-specific harvest kinetics is limited.